Geoffrey Gurtner, MD, FACS
Vice Chairman of Surgery for Research
Stanford University School of Medicine
257 Campus Drive West, GK-201
Stanford, CA 94305-5148
Dr. Geoffrey C. Gurtner is the Johnson and Johnson Professor of Surgery and Biomedical Engineering (by courtesy) and Materials Science (by courtesy) at Stanford University. Clinically, Dr. Gurtner is the Director of the Stanford Wound Center and the Stanford Program in Applied Regenerative Medicine (SARM). He is the author of over 280 peer-reviewed publications and is an Editor for two major textbooks in the field: Grabb & Smith's Plastic Surgery and Plastic Surgery. Dr. Gurtner was awarded the James Barrett Brown Award in both 2009 and 2010 and has been named "researcher of the year" by the ASPS, AAPS and numerous other professional organizations. Dr. Gurtner runs an NIH and DoD funded laboratory examining how physical stimuli (mechanical and chemical) alter the human response to injury. This has led to the development of new technologies for which Dr. Gurtner has received 20 issued patents and over 100 patent applications. Dr. Gurtner has founded several venture backed start-up companies, including Neodyne Biosciences (www.neodynebio.com) and Arresto Biosciences, acquired by Gilead (NASDAQ:GILD) in 2011. Dr. Gurtner was also a founding partner at Tautona Group (www.tautonagroup.com), an early stage life science fund that has created novel biomedical technologies that have been sold to industry leading companies, such as Allergan (NYSE:AGN), Novadaq (NASDAQ:NVDQ), and Acelity/KCI (San Antonio, TX).
Alan Wells, MD DMSc
Dr. Alan Wells is the Thomas J. Gill III Professor of Pathology and the Executive Vice-Chairman of the Department of Pathology at the University of Pittsburgh. In addition, Wells is a Professor of Bioengineering and Computational Biology (secondary appointments) and a Staff Physician at the Veterans Administration Medical Center in Pittsburgh, Pennsylvania. He also serves as the Medical Director for the UPMC System Clinical Laboratories.
Wells holds an AB in Biochemistry from Brown University (1979) and received his doctorate (DMSc) in Tumor Biology from the Karolinska Institute in Stockholm, Sweden, in 1982. Returning to Providence, Rhode Island, he received his MD from Brown University in 1988. Following his studies, Wells completed a postdoctoral fellowship in Tumor Biology at the University of California in San Francisco, California, and a Residency in Laboratory Medicine at the University of California in San Diego, California. He has won numerous awards and has been recognized locally and nationally for his research, mentoring and clinical service, including being elected to the American Society for Clinical Investigation (ASCI) and American Association of University Pathologists (AAUP/Pluto Club).
Within his laboratory, Wells and his research team are aiming to gain a better understanding of how cells respond to their local environment. Ultimately, the importance of his research flows from the provision of reinforcing insights and novel avenues for exploration into the basic signaling pathways, as well as functioning of entire organisms. Currently, Wells is concentrating his research efforts towards gaining further knowledge of the conditions of dysregulated (tumor dissemination and chemoresistance of tumors) and orchestrated (wound healing and organogenesis) responses. These studies are performed in vitro, in animal models, validating in human specimens, and employing novel state-of-the-art all human microphysiological systems.
Kenneth Liechty, MD
Dr. Kenneth Liechty’s research has been focused primarily in the field of wound healing, the response to injury, and regenerative medicine, with an emphasis on elucidating the mechanisms involved in the regenerative response to injury in the fetus, the role of inflammation and oxidative stress in tissue repair, and the correction of abnormal healing in the adult. Dr. Liechty’s research team has pioneered the role of dysregulated microRNAs in the diabetic wound healing impairment, and the mechanisms of the correction of this wound healing impairment with stem cell and gene therapy. The Liechty research team is developing novel treatment paradigms using small molecule therapeutics including the microRNA conjugated nanoparticles, as well as stem cells and gene therapy strategies to promote healing and tissue regeneration in multiple tissues by modulating the inflammatory response, angiogenesis, the composition of the extracellular matrix, macrophage polarization, and progenitor cell content. Dr. Liechty’s research team has also developed and published the first report of mammalian cardiac regeneration in a large animal model following in utero myocardial infarction and has contributed significantly to the understanding of regenerative healing in the heart, skin and tendon, and the correction of impaired healing in diabetics. The goal of Dr Liechty’s research approach in regenerative medicine is to restore normal tissue architecture and function and to prevent the complications of impaired healing or scar formation after injury.
Sashwati Roy, PhD
Professor of Surgery
Director, Clinical Research IUH Comprehensive Wound Center (CWC)
Indiana Center for Regenerative Medicine and Engineering (ICRME)
School of Medicine
444A MRLB; 975 Walnut Street Indianapolis IN
Sashwati Roy, PhD is a tenured Professor in the Department of Surgery, Indiana University School of Medicine. She serves as the Director for Clinical Research at the Comprehensive Wound Center at the Indiana University Health Comprehensive Wound Center (IUH CWC), an NIH/NIDDK funded Center. She is an expert in inflammation and diabetic wounds. Her research interests include wound inflammation in T2DM, Innate immune cell function, role of miRNA in tissue repair processes. Dr. Roy has over 225 peer review publications. Her work has been cited over 15000 times. Dr. Roy’s research program is funded by multiple national level funding including National Institute of Health, USA and Department of Defense (DoD, USA). Dr. Roy is a permanent member for the Surgery Anesthesia Trauma Study Setion at NIH. She also routinely serves as adhoc reviewer for other multiple NIH, VA study sections, and international grant review panels including Ministry of Health Italy as well as for prestigious journals. She has served as committee chairs, secretary, and executive board member at the national Wound Healing Society, USA . She is currently serving as the President for WHS.
|Praveen Arany||Secretary (2019-2022)
Bio coming soon...
Herbert B. Slade, MD
Chisholm Clinical Research Services
2436 Medford Court West
Fort Worth, TX 76109
Dr. Slade is a dual board-certified subspecialist in pediatrics and clinical immunology with more than 25 years of industry-based experience in clinical research. After holding academic appointments at the University of Michigan and Cornell University Medical Center, he was recruited from academia to work with Dr. Jonas Salk on an HIV therapeutic vaccine joint venture, taking the position of Director of AIDS and Immunology at RhÃ´ne-Poulenc Rorer.
From there Dr. Slade went on to join 3M Pharmaceuticals as Chief Medical Officer. During his twelve years at 3M, Dr. Slade oversaw the development and licensure of multiple products, including a groundbreaking new class of immune response modifiers for viral infections and cancer. When 3M sold its pharma business, Dr. Slade joined DFB Pharmaceuticals in Fort Worth, TX, where he served as Chief Medical Officer for Healthpoint Biotherapeutics. Smith & Nephew plc acquired Healthpoint in 2012, bringing Dr. Slade into the realm of medical devices in the role of CMO and Sr.VP of Research & Development for the wound care division through the end of 2016.
Dr. Slade earned his undergraduate degree in biology from Hamilton College in Clinton, N.Y., followed by his medical degree from State University of New York (SUNY) Upstate Medical University in Syracuse, N.Y.
Dept of Dermatology and Microbiology
University of Pennsylvania
G1007 BRB II/III
421 Curie Blvd
Philadelphia, PA 19104
|Elizabeth Grice, PhD (2017-2020)
Elizabeth A. Grice, PhD, is an Associate Professor with tenure in the Departments of Dermatology and Microbiology (secondary) at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA. Dr. Grice began her scientific training as an undergraduate at Luther College, then received a PhD in Human Genetics from Johns Hopkins University in 2006. Dr. Grice then completed a post-doctoral fellowship at the NIH, where her pioneering work revealed the vast topographic and temporal diversity of the healthy human skin microbiome. At that time, she developed a scientific interest in microbial roles in impaired wound healing, and received an NIH K99-R00 Pathway to Independence Award to investigate microbial-host interactions in diabetic wound healing. Since 2012, Dr. Grice has led a research group of multi-disciplinary scientists and trainees, integrating genomics, microbiology, skin biology, and bioinformatics to investigate the skin microbiome and its roles in cutaneous barrier function, tissue repair, and colonization resistance to pathogens. A major focus of the laboratory is unraveling the microbial contributions to impaired healing and clinical outcomes in diabetic foot ulcers. Dr. Grice's research is funded by grants from the NIH (NINR, NIAMS, NIEHS, NIAID), the Burroughs Welcome Fund, and the Dermatology Foundation. Dr. Grice has received numerous awards for her work, including the Penn Medicine Michael S. Brown New Investigator Award, the Penn One Health Award, the Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award, and the Sun Pharma Research Award from the Dermatology Foundation. She serves on the editorial board of mSystems and Microbiome. Dr. Grice is Co-Chair of the 2019-2020 WHS Program Committee.
Division of Plastic Surgery
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115
|Dennis P. Orgill, MD, PhD (2017-2020)
Dr. Dennis Orgill is a Plastic Reconstructive Surgeon at Brigham and Women’s Hospital (BWH). In 1978, he attended MIT as a graduate student and worked with Drs. Yannas and Burke in developing an artificial skin for burn victims. He was involved in the pre-clinical and early clinical studies performed at Massachusetts General Hospital and the Shiners Burn Institute. He completed Medical School at Harvard as well as residencies in Surgery and Plastic Surgery at BWH and Harvard. He then started on staff in the Plastic Surgery Division at BWH in 1992 where he also started the Tissue Engineering and Wound Healing Laboratory that has published over 100 papers and received numerous grants. He became the Medical Director of the newly formed BWH Wound Center in 2009. This Center has cared for thousands of patients, been involved in several clinical trials and has sponsored a bi-annual regional Wound Care Conference. In 2013 he was appointed as the only surgeon on the Board of Directors of the Hidradenitis Foundation, which advocates for better treatments of patients with this difficult disease. He looks forward to advocating for improved wound care for the many patients with acute and chronic wounds throughout the world.
New Indications Discovery Unit
Novartis Biomedical Research Institute
PO Box 290790
Charlestown, MA 02129
Work Phone: (253) 691-9197
|Vickie Rae Driver, DPM, MS (2018-2021)
Dr Vickie R. Driver is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Ma and RI and is board certified in foot surgery by the American Board of Podiatric Surgery. She has recently been nominated as Fellow, Royal College of Physicians and Surgeons-Glasgow, PM. Her career has a special emphasis on wound healing and limb preservation and she is an outspoken ambassador for progressive change in this field.
Dr. Driver is a Professor of Surgery in the Department of Orthopedics at Brown University (Clinical). She has recently completed her tenure as president for the Advancement of Wound Care Association (AAWC), and has served for 9 years on the Board of Directors. She also proudly serves as a member of the Wound Healing Society (WHS) Board of Directors- member at large and chair-Industry relations and as member Board of Directors for the Critical Limb Ischemia (CLI) Global Society and chair wound healing committee.
She has successfully chaired an initiative to expand the wound healing clinical endpoints considered by FDA. She proposed a combined effort between the WHS and AAWC to develop the Wound-care Experts/FDA-Clinical Endpoints Project [WEF-CEP] to strategically identify clinically meaningful, evidence-based and patient-centered wound care endpoints that are relevant for clinical research and trials. The goal is to collaboratively work with the FDA to expand the list of acceptable primary endpoints, recognizing that new and innovative treatments, devices and drugs may not have complete healing as the focus. Furthermore, validated endpoints other than complete healing will promote improved clinical trial design and will reduce the time for discoveries to reach our patients. Over the past three years, through ongoing interaction with the FDA InterCenter Wound Healing Work Group [ICWHWG], the WEF-CEP team has conducted a wide reaching Clinician Survey with 628 participating wound care experts, completed an extensive literature review for 28 wound care endpoints using the FDA criteria for a validated endpoint, published the clinical survey results in WRR, is in process to publish the research phase results and is currently conducting a Patient Survey to augment the findings of the Clinician Survey. Formal collaboration with the FDA established to execute on the WEF CEP work is on-going.
As principle investigator, she has served on and initiated more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has co-authored over 100 publications and abstracts.
Dr. Driver is Director, Translational Medicine Wound Healing at Novartis Institute for BioMedical Research. She is dedicated to making a scientific contribution to both the understanding of the natural history of disease and the discovery of new therapies and diagnostics to advance the treatment of patients who suffer with wounds and are at risk of limb loss.
Plastic and Reconstructive Micro Surgeon
Duke University Medical Center (DUMC)
Durham, North Carolina
|Howard Levinson, MD (2018-2021)
Howard Levinson, MD, FACS is a double board certified General Surgeon and Plastic and Reconstructive Micro Surgeon at Duke University Medical Center (DUMC). He is an Associate Professor in the Departments of Surgery and Pathology. Dr Levinson is: (1) an expert in wound repair and scarring, (2) the Director of Plastic Surgery Research and the PI of the Wound Healing and Fibrosis Laboratory at DUMC, and (3) a nationally recognized key opinion leader. He has been an ad hoc member of multiple Department of Defense and NIH study sections, including SBIR/STTR committees, and has been PI of NIH grants, NCBiotech grants, a Coulter translational grant, a Duke Translational Medical Institute Translational Grant, and MedBlue translational grant. He holds several patents, and has expertise in translational research in the peri-operative space. He is Founder of Deep Blue Medical Advances, a medical device company whose mission is to commercial Medical Devices.
Patient Care: Dr Levinson cares for patients both at DUMC and the Veterans Administration Hospital in Durham, North Carolina. His practice is >90% reconstructive and frequently includes reconstruction of complex abdominal wall defects. He is recognized by his peers on a national level for his clinical expertise as can be noted by his serving as a speaker and moderator for multiple loco-regional and national meetings.
Director of Plastic Surgery Research: Dr Levinson's interdisciplinary team uses in vitro and in vivo pre-clinical models to understand disease pathogenesis and develop new technologies. He works closely with biomedical engineers and basic scientists on different translational projects. He designs and oversees clinical trials. His research is funded by intramural as well as extramural grants. He is past Chairman of the Plastic Surgery Foundation Research Fundamentals Workshop, Chairman of the Plastic Surgery Foundation Research Education Committee and Basic Science Study Section, and Chairman of the Plastic Surgery Research Council. He is a member of the Board of Directors for the American Society of Plastic Surgery.
Dr Levinson has consulted for GlaxoSmithKline, Johnson and Johnson, Heraeus Pharmaceuticals, Exoxemis, Allergan. He serves on the Wound Care Advisory board for Cardinal Health. He has multiple collaborations with investigators both within and outside of DUMC. He has served as an ad-hoc reviewer for several scientific journals including but not limited to The New England Journal of Medicine, Annals of Surgery, The American Journal of Physiology: Cell Physiology, e-PLOS, Journal of Surgical Research, Plastic and Reconstructive Surgery, and Molecular and Cellular Biochemistry.
|Kath Bogie (2018-2021)
Dr. Bogie is a biomedical engineer committed to pursuing patient-centered translational research. Dr. Bogie currently holds appointments as Associate Professor in the Dept of Orthopaedics at Case Western Reserve University (CWRU) and as Senior Research Scientist at the Louis Stokes Cleveland Dept of Veterans Affairs Medical Center, where she is also Director of Health Maintenance and Monitoring within the Advanced Platform Technology Center. At CWRU, she directs the Additive Manufacturing for Biotechnology Core, supporting biomedical additive manufacturing. Dr. Bogie received her D.Phil in Biomedical Engineering from the University of Oxford, England. Her initial post-doctoral appointment was at the National Spinal Cord Injuries Centre (NSIC), Aylesbury, England, with a concurrent appointment as Associate Clinical Scientist at Queen Mary and Westfield College, University of London. At NSIC, she established a Wheelchair Seating Clinic for individuals with spinal cord injury. The multivariate quantitative non-invasive tissue health evaluation tool she developed there has since been applied in multiple clinical studies. At NSIC, she noticed that many wheelchair users were prevented from achieving their full functional potential due to tissue health problems. The huge detriment on all aspects of the affected individual's life motivated her to dedicate her career to the multiple challenges of wound management. Dr. Bogie's lab works on primary and secondary prevention of chronic wounds through novel clinically –focused approaches. The overarching goal is to reduce the fear of developing a chronic non-healing wound. Dr. Bogie has received continuous support for her research program for over 17 years, including funding from the DoD Spinal Cord Injury Research Program, the Dept. of Veterans Affairs Rehabilitation Service and the Craig H Neilsen Foundation. Current translational research includes studies to determine why some people experience a continuous cycle of pressure injuries while others remain pressure injury free, complemented with smart technology development to address these issues. Dr. Bogie has been recognized internationally as an expert in research areas related to wound care, has published over 50 papers and book chapters and given multiple national and international presentations. Dr Bogie is on the Editorial Boards of Journal of Tissue Viability and the Journal of Rehabilitation and Assistive Technologies Engineering and is an active referee for multiple scientific journals and numerous other national and international grant review panels.
Dr. Bogie joined the Wound Healing Society in 2011, and has served as an active member of the Education Committee since joining WHS. As a biomedical engineer working on translational studies in wound care, Dr. Bogie is committed to building effective interdisciplinary teamwork. There are a wealth of basic science and early clinical trials being carried out in wound care research, but all too often these fail to translate, in part due to lack of communication between different specialties. The Wound Healing Society is the home that fosters interactions. Moving outside our silos of expertise and working with others allows the field to gain from diversity of experience. As a member of the WHS Board of Directors, Dr. Bogie looks forward to working to enhance interdisciplinary interactions in wound care research.
|Rivkah Isseroff (2018-2021)
Bio coming soon...
|Brian Eliceiri (2019-2022)
Bio coming soon...
|Timothy King (2019-2022)
Bio coming soon...
|Lisa Gould (2019-2022)
Bio coming soon...
Members at Large
The Ohio State University
1645 Neil Avenue
129 Hamilton Hall
Columbus, OH 43210
|Traci Wilgus, PhD (2019-2020)
Dr. Wilgus is an Associate Professor in the Department of Pathology at The Ohio State University. She earned her Ph.D. from Ohio State and completed post-doctoral training at Loyola University Medical Center. She was a junior faculty member at University of Illinois-Chicago before accepting a tenure-track position at Ohio State in 2008. Her lab studies the role of inflammation and angiogenesis in wound healing and skin carcinogenesis, with a special interest in understanding mechanisms of scarless healing in fetal skin. Dr. Wilgus frequently serves as a reviewer for manuscripts and grants in the area of wound healing and is a member of the editorial boards for Wound Management and Prevention, Advances in Wound Care, and Journal of Investigative Dermatology.
Dr. Wilgus joined the Wound Healing Society as a graduate student in 2000 and has served the WHS in various capacities over the last decade. She has served on the Website Committee (2008-2011) and Awards Committee (2011-2014), and has been a member of the Program Committee since 2010. She was Co-Chair of the WHS annual scientific meeting in 2015, served on the Board of Directors from 2013-2016, and was Secretary from 2016-2019.
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery,
Department of Public Health Sciences
University of Miami Miller School of Medicine
|Robert S. Kirsner, MD, PhD (2019-2020)
Dr. Kirsner is Chairman and Harvey Blank Professor in the Dr. Phillip Frost Dermatology in the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. He is Chief of Dermatology at the University of Miami Hospital and Clinics and Jackson Memorial Hospital and directs the University of Miami Hospital Wound Center. Dr. Kirsner received his undergraduate degree from Texas A&M University, his medical degree from the University of Miami and a PhD in epidemiology from the University of Miami, after he completed his clinical training. His clinical training included internal medicine, a clinical and research fellowship in wound healing and dermatology at the University of Miami. His research interests include Wound Healing and Skin Cancer Epidemiology. Dr. Kirsner serves on the editorial boards for a number of journals in dermatology and wound healing and serves in national leadership positions in both Wound Healing and Dermatology, including currently serving on the American Academy of Dermatology Board of Directors. In addition to career development awards, foundation, industry sponsored funding and CDC funding, he currently leads or is part of a number of NIH funded grants. Independent of books, book chapters and abstracts, he has published over 525 articles.
Representing Wound Healing Society Foundation on the Board of Directors
Laura K.S. Parnell Ex-Officio
Founder & President
6522 Harbor Mist
Missouri City, TX 77459
Representing Wound Repair and Regeneration on the Board of Directors
Jeffrey M. Davidson, PhD Ex Officio
Editor in Chief, Wound Repair and Regeneration
Professor of Pathology, Microbiology and Immunology
Vanderbilt University School of Medicine
1161 21St. Ave. S
Nashville, TN 37232-2561
Brian Eliceiri, PhD Ex-Officio
Publications Committee Chair
Department of Surgery
University of California San Diego
212 Dickinson Street, MC 8236
San Diego, CA 92103
To contact a Board member, please email WHS or call 978-927-8330.